Overview

Acetazolamide for Treatment Resistant Schizophrenia

Status:
Not yet recruiting
Trial end date:
2024-06-30
Target enrollment:
Participant gender:
Summary
This is a double blind adjunctive randomized controlled trial for schizophrenia using acetazolamide.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Vishwajit Nimgaonkar, MD PhD
Collaborator:
Stanley Medical Research Institute
Treatments:
Acetazolamide